The TOPAZ-1 study: a plain language summary describing durvalumab and chemotherapy for advanced biliary tract cancer
This Plain Language Summary of Publication article from Future Oncology describes the result of a phase 3 study called TOPAZ-1. The study looked at treatment durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC).
Visit Future Medicine using the link to read the article.
The original article on which this summary is based on is called ‘Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer’ and was published in NEJM Evidence.
Visit NEJM Medicine using the link to read the article.